Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response at 10 weeks · people with active UC
Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · Patients with quiescent ulcerative colitis
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Acute pancreatitis · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
1 finding from 1 review
Intervention not reported
Bone marrow suppression · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
1 finding from 1 review
Any adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review